This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Targeting Prostate Cancer Subtype 1 by Forkhead box M1 Pathway Inhibition
Kirsi Ketola1, Ravi S.N Munuganti1, Alastair Davies1, Ka Mun Nip1, Jennifer L. Bishop1, Amina
Zoubeidi1,2
1: Vancouver Prostate Centre, Vancouver, BC, CAN 2: University of British Columbia, Faculty of Medicine, Department of Urology, Vancouver BC, CAN
Running title: Targeting PCS1 by FOXM1 Pathway Inhibition
Financial support. This work (AZ) is supported by Prostate Cancer Canada and proudly funded by the Movember Foundation (T2013-01). AZ is supported by Michael Smith foundation for Health Research, KK is supported by Prostate Cancer Canada and US Department of Defense (PC141530). RSNM is supported by Prostate Cancer Canada and Michael Smith foundation for Health Research, AD is supported by Canadian Institute for Health Research and Prostate Cancer Foundation, JLB was supported by Prostate Cancer Foundation.
Corresponding author: Amina Zoubeidi, Ph.D Associate Professor Department of Urologic Sciences, UBC 2660 Oak Street Vancouver BC V6H 3Z6, Canada Phone: (604) 875-4111 # 68880 Fax: (604) 875-5654 Email: [email protected]
Conflict of Interest There are no conflicts of interest.
Word count: 4291 Total number of figures and tables: 5 Figures, 1 Table, 7 Supplementary Figures, 3 Supplementary Tables
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. PubMed PMID: 25559415. 2. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002 Jul;168(1):9-12. PubMed PMID: 12050481. 3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004 Jan;10(1):33-9. PubMed PMID: 14702632. 4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. PubMed PMID: 22894553. 5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. PubMed PMID: 21612468. Pubmed Central PMCID: 3471149. 6. Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015 Dec;15(12):701-11. PubMed PMID: 26563462. Pubmed Central PMCID: 4771416. 7. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24;375(9724):1437-46. PubMed PMID: 20398925. Pubmed Central PMCID: 2948179. 8. Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. 2015 Apr 2;34(14):1745-57. PubMed PMID: 24837363. Pubmed Central PMCID: 4333106. 9. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013 Sep;3(9):1020-9. PubMed PMID: 23779130. 10. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013 Sep;3(9):1030-43. PubMed PMID: 23842682. 11. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013 Jan 15;73(2):483-9. PubMed PMID: 23117885. Pubmed Central PMCID: 3549016. 12. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014 Sep 11;371(11):1028-38. PubMed PMID: 25184630. Pubmed Central PMCID: 4201502. 13. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016 Mar;22(3):298-305. PubMed PMID: 26855148. Pubmed Central PMCID: 4777652. 14. You S, Knudsen BS, Erho N, Alshalalfa M, Takhar M, Al-Deen Ashab H, et al. Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Res. 2016 Sep 1;76(17):4948-58. PubMed PMID: 27302169. 15. Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015 Sep 18;349(6254):1351-6. PubMed PMID: 26383955. Pubmed Central PMCID: 4872391. 16. Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, et al. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discov. 2017 Jan;7(1):54-71. PubMed PMID: 27784708. 17. Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, et al. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. Mol Cancer Ther. 2013 May;12(5):567-76. PubMed PMID: 23493310.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
18. Duan QN, Flynn C, Niepel M, Hafner M, Muhlich JL, Fernandez NF, et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Research. 2014 Jul 1;42(W1):W449-W60. PubMed PMID: WOS:000339715000074. English. 19. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013 Apr 2;6(269):pl1. PubMed PMID: 23550210. Pubmed Central PMCID: 4160307. 20. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, et al. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome biology. 2008;9(9):R139. 21. Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 2011 Jul;39(Web Server issue):W270-7. PubMed PMID: 21624888. Pubmed Central PMCID: 3125772. 22. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004 Mar 25;47(7):1739-49. PubMed PMID: 15027865. 23. Chemical Computing Group ICMOEMCM, Quebec, Canada, 2008; . www. chemcomp.com. 24. Lomenick B, Jung G, Wohlschlegel JA, Huang J. Target identification using drug affinity responsive target stability (DARTS). Curr Protoc Chem Biol. 2011 Dec 1;3(4):163-80. PubMed PMID: 22229126. Pubmed Central PMCID: 3251962. Epub 2012/01/10. Eng. 25. Petrovic V, Costa RH, Lau LF, Raychaudhuri P, Tyner AL. Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin. Cancer Biol Ther. 2010 Jun 15;9(12):1008-16. PubMed PMID: 20372080. Pubmed Central PMCID: 3005150. Epub 2010/04/08. eng. 26. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006 Sep 29;313(5795):1929-35. PubMed PMID: WOS:000240832200043. English. 27. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, et al. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol. 2008;9(9):R139. PubMed PMID: 18803840. Pubmed Central PMCID: 2592717. 28. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010 Jul 13;18(1):11-22. PubMed PMID: 20579941. Pubmed Central PMCID: 3198787. 29. Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer cell. 2014 May 12;25(5):638-51. PubMed PMID: 24823640. Pubmed Central PMCID: 4051317. Epub 2014/05/16. eng. 30. Kalin TV, Wang IC, Ackerson TJ, Major ML, Detrisac CJ, Kalinichenko VV, et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 2006 Feb 1;66(3):1712-20. PubMed PMID: 16452231. Pubmed Central PMCID: 1363687. Epub 2006/02/03. eng. 31. Chen Y, Ruben EA, Rajadas J, Teng NN. In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer. Bioorg Med Chem. 2015 Aug 1;23(15):4576-82. PubMed PMID: 26164623. 32. Gormally MV, Dexheimer TS, Marsico G, Sanders DA, Lowe C, Matak-Vinkovic D, et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun. 2014 Nov 12;5:5165. PubMed PMID: 25387393. Pubmed Central PMCID: 4258842. 33. Wong JC, Jack MM, Li Y, O'Neill C. The epigenetic bivalency of core pancreatic beta-cell transcription factor genes within mouse pluripotent embryonic stem cells is not affected by knockdown of the polycomb repressive complex 2, SUZ12. PLoS One. 2014;9(5):e97820. PubMed PMID: 24845830. Pubmed Central PMCID: 4028244.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
34. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008 May;40(5):499-507. PubMed PMID: 18443585. Pubmed Central PMCID: 2912221. 35. Bella L, Zona S, Nestal de Moraes G, Lam EW. FOXM1: A key oncofoetal transcription factor in health and disease. Seminars in cancer biology. 2014 Dec;29:32-9. PubMed PMID: 25068996. 36. Halasi M, Gartel AL. FOX(M1) news--it is cancer. Mol Cancer Ther. 2013 Mar;12(3):245-54. PubMed PMID: 23443798. Pubmed Central PMCID: 3596487. 37. Koo CY, Muir KW, Lam EW. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta. 2012 Jan;1819(1):28-37. PubMed PMID: 21978825. 38. Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y, et al. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. Cancer Discov. 2017 Jul;7(7):736-49. PubMed PMID: 28411207. Pubmed Central PMCID: 5501744. 39. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017 Jan 06;355(6320):78-83. PubMed PMID: 28059767. Pubmed Central PMCID: 5367887. 40. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, et al. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA oncology 2017 doi 10.1001/jamaoncol.2017.0751. 41. Lefebvre C, Rajbhandari P, Alvarez MJ, Bandaru P, Lim WK, Sato M, et al. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol Syst Biol. 2010 Jun 08;6:377. PubMed PMID: 20531406. Pubmed Central PMCID: 2913282. 42. Wang IC, Ustiyan V, Zhang Y, Cai Y, Kalin TV, Kalinichenko VV. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.). Oncogene. 2014 Nov 13;33(46):5391-6. PubMed PMID: 24213573. 43. Hegde NS, Sanders DA, Rodriguez R, Balasubramanian S. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem. 2011 Sep;3(9):725-31. PubMed PMID: 21860463. Epub 2011/08/24. eng.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901
Published OnlineFirst September 12, 2017.Clin Cancer Res Kirsi Ketola, Ravi SN Munuganti, Alastair Davies, et al. Pathway InhibitionTargeting Prostate Cancer Subtype 1 by Forkhead box M1
Updated version
10.1158/1078-0432.CCR-17-0901doi:
Access the most recent version of this article at:
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2017/09/12/1078-0432.CCR-17-0901To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/1078-0432.CCR-17-0901